Cervarix already is approved in nearly 100 other countries, but has been delayed in the U.S. since 2007, when the FDA said it needed additional data. The vaccine blocks the two main viruses that cause most cases of cervical cancer.
An approval from FDA would allow London-based Glaxo to compete against Merck's blockbuster vaccine Gardasil, which has been on the market here since 2006.
More HealthCheck related links:
